Press release
Severe Asthma Market: High-Growth Opportunities for Investors to 2034 - DelveInsight | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca
DelveInsight's "Severe Asthma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Severe Asthma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/severe-asthma-market [https://www.delveinsight.com/report-store/severe-asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Severe Asthma Market Report:
*
The Severe Asthma market size was valued approximately USD 7.8 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
*
In December 2025, GSK plc (LSE/NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in adults and pediatric patients aged 12 years and older. The approval is supported by results from the Phase III SWIFT-1 and SWIFT-2 trials, in which depemokimab achieved sustained reductions in asthma exacerbations with twice-yearly dosing compared with placebo, when added to standard of care.
*
In July 2025, Asthma severity is driven by multiple inflammatory pathways, making uniform treatment challenging. Researchers are turning to precision medicine, which identifies disease subtypes using biomarkers to customize therapies. By conducting trials that match patients with treatments tailored to their biological profiles, investigators aim to replicate strategies proven effective in cancer research. This method, called a platform trial, allows for the simultaneous evaluation of several interventions in enrolled patients.
*
In May 2025, Fresh Phase 3 WAYFINDER results, shared at ATS 2025, show that tezepelumab (Tezspire) treatment can greatly reduce or even eliminate oral corticosteroid (OCS) use in adults with OCS-dependent severe asthma. Steroid dependence remains a major concern in severe asthma, as prolonged OCS use is linked to serious side effects, including cardiovascular, bone, metabolic, gastrointestinal, psychiatric issues, and adrenal insufficiency.
*
Among the European countries, the United Kingdom had the largest market size, reaching USD 430 million in 2023.
*
In 2023, the total diagnosed prevalent cases of asthma in the 7MM were approximately 43 million in adults and around 11 million in the pediatric population. These numbers are expected to increase significantly by 2034.
*
In 2023, the total number of diagnosed prevalent cases of Severe Asthma across the 7MM reached 5.1 million, accounting for roughly 9% of all diagnosed asthma cases. These cases are projected to increase significantly by 2034.
*
In 2023, the UK had the highest number of diagnosed prevalent cases of Severe Asthma (0.4 million) among the EU4 countries and the UK, followed by France with 0.3 million cases. Conversely, Spain had the lowest number of diagnosed Severe Asthma cases within the same group.
*
As per DelveInsight analysis, in Japan, the severity-specific cases segmented as intermittent, mild, moderate, and severe cases of asthma were observed to be 4 million, 0.8 million, 1 million, and 0.8 million cases, respectively in 2023. The severity-specific cases are expected to change by 2034.
*
In 2023, the US had roughly 1.2 million cases of both Type-2 inflammation severe asthma and non-type-2 inflammation severe asthma.
*
The Severe Asthma pipeline is dynamic and includes promising candidates such as GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri/Trixeo/BGF MDI) by AstraZeneca, among others, anticipated to be launched between 2023 and 2032.
*
Key Severe Asthma Companies: Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others
*
Key Severe Asthma Therapies: Cinqair (reslizumab), Fasenra (benralizumab), PT010, Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others
*
The Severe Asthma epidemiology based on gender analyzed that females are more susceptible to suffering from asthma when compared to the male population, in the 7MM
*
The Severe Asthma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Asthma pipeline products will significantly revolutionize the Severe Asthma market dynamics.
Severe Asthma Overview
Severe asthma is a chronic respiratory condition characterized by persistent and intense symptoms that are difficult to control despite high doses of standard asthma medications. Unlike mild or moderate asthma, severe asthma often requires more aggressive treatment and can significantly impact a person's quality of life.
To Know in detail about the Severe Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Asthma Market Forecast [https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Severe Asthma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Severe Asthma Epidemiology Segmentation:
The Severe Asthma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Severe Asthma
*
Prevalent Cases of Severe Asthma by severity
*
Gender-specific Prevalence of Severe Asthma
*
Diagnosed Cases of Episodic and Chronic Severe Asthma
Download the report to understand which factors are driving Severe Asthma epidemiology trends @ Severe Asthma Epidemiology Forecast [https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Severe Asthma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Asthma market or expected to get launched during the study period. The analysis covers Severe Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Severe Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Severe Asthma Therapies and Key Companies
*
Cinqair (reslizumab): Teva Pharmaceutical
*
Fasenra (benralizumab): AstraZeneca
*
PT010: AstraZeneca
*
Verekitug (UPB-101): Upstream Bio Inc.
*
FB704A: Oneness Biotech Co.
*
TQC2731 injection: Chia Tai Tianqing Pharmaceutical
*
Benralizumab Prefilled Syringe: Nantes University Hospital
*
Nebulized budesonide: Hamad Medical Corporation
*
povorcitinib: Incyte Corporation
*
CM326: CSPC ZhongQi Pharmaceutical
*
CM310: CSPC ZhongQi Pharmaceutical
*
Benralizumab: AstraZeneca
*
610: Sunshine Guojian Pharmaceutical
*
Rocatinlimab: Amgen
*
Dexpramipexole Dihydrochloride: Areteia Therapeutics
*
Amlitelimab: Sanofi
*
GSK3511294 (Depemokimab): GlaxoSmithKline
*
Mepolizumab: GlaxoSmithKline
*
Flamboyant 200/12: EMS
*
AD17002: Advagene Biopharma Co.
*
TEV-56248: Teva Branded Pharmaceutical
*
FB825: Oneness Biotech Co.
Discover more about therapies set to grab major Severe Asthma market share @ Severe Asthma Treatment Landscape [https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Severe Asthma Market Drivers
*
Rising prevalence of severe and uncontrolled asthma, particularly among adults with long-standing disease
*
Growing adoption of biologic therapies targeting IgE, IL-5, IL-4/IL-13 pathways, improving outcomes in severe asthma
*
Increased disease awareness and improved phenotyping and biomarker-based diagnosis
*
Strong clinical pipeline with next-generation biologics and targeted small-molecule therapies
*
Favorable reimbursement policies for high-value biologics in developed healthcare markets
Severe Asthma Market Barriers
*
High cost of biologic therapies, limiting accessibility in low- and middle-income regions
*
Strict eligibility criteria for biologics, restricting treatment to specific patient subgroups
*
Long-term safety and real-world effectiveness concerns for newer targeted therapies
*
Treatment adherence challenges due to injectable dosing and chronic therapy requirements
*
Competition from biosimilars and pricing pressure affecting market growth
Scope of the Severe Asthma Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Severe Asthma Companies: Teva Pharmaceutical, AstraZeneca, Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others
*
Key Severe Asthma Therapies: Cinqair (reslizumab), Fasenra (benralizumab), PT010, Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others
*
Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
*
Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Severe Asthma Unmet Needs, KOL's views, Analyst's views, Severe Asthma Market Access and Reimbursement
To know more about Severe Asthma companies working in the treatment market, visit @ Severe Asthma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Severe Asthma Market Report Introduction
2. Executive Summary for Severe Asthma
3. SWOT analysis of Severe Asthma
4. Severe Asthma Patient Share (%) Overview at a Glance
5. Severe Asthma Market Overview at a Glance
6. Severe Asthma Disease Background and Overview
7. Severe Asthma Epidemiology and Patient Population
8. Country-Specific Patient Population of Severe Asthma
9. Severe Asthma Current Treatment and Medical Practices
10. Severe Asthma Unmet Needs
11. Severe Asthma Emerging Therapies
12. Severe Asthma Market Outlook
13. Country-Wise Severe Asthma Market Analysis (2020-2034)
14. Severe Asthma Market Access and Reimbursement of Therapies
15. Severe Asthma Market Drivers
16. Severe Asthma Market Barriers
17. Severe Asthma Appendix
18. Severe Asthma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-asthma-market-highgrowth-opportunities-for-investors-to-2034-delveinsight-sanofi-glaxosmithkline-ems-oneness-biotech-incyte-corp-cspc-zhongqi-pharma-astrazeneca]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Asthma Market: High-Growth Opportunities for Investors to 2034 - DelveInsight | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca here
News-ID: 4384803 • Views: …
More Releases from ABNewswire
The Optimal Binary Arena: Stockity Engineered Environment
Image: https://www.abnewswire.com/upload/2026/02/485446e1a61934a05525230d899f8d3b.jpg
The decision to engage in binary options trading requires courage, discipline, and, most crucially, the right operational ground. The Stockity [https://stockity.ai/id/] platform distinguishes itself not merely as a broker, but as a meticulously engineered environment specifically crafted to mitigate the inherent psychological and technical turbulence of high-frequency speculation. Its design philosophy centers on transforming a high-risk activity into a controlled, accessible, and intellectually stimulating challenge for the active trader.
Engineering…
Female Aestheticians Build National Skincare Brand on Three Decades of Clinical …
Corrective Skin LLC brings professional aesthetician expertise directly to consumers with a skincare line refined over 30 years of clinical practice. The mother-daughter team has built a growing TikTok presence that showcases genuine results from their signature EGF Healing Cream, attracting informed consumers who value transparency and proven efficacy over marketing hype.
In an era when skincare brands emerge constantly with bold claims and celebrity endorsements, Corrective Skin LLC stands apart…
Canine Weight Set Taps Into Growing Pet Wellness Trend with Performance-Focused …
As pet owners increasingly prioritize their dogs' physical and mental health, Canine Weight Set offers a solution that addresses both needs through weighted resistance training. The company's specialized vest system represents an emerging approach in the pet wellness industry, applying athletic training science to everyday dog exercise routines.
The pet wellness industry is experiencing a significant evolution as owners move beyond basic care to embrace optimization strategies previously reserved for human…
Chinese New Year Shipping Uninterrupted - Nihaojewelry Mexico Warehouse Open Feb …
Image: https://www.abnewswire.com/upload/2026/02/8e124b6a7b95e476a5f18b10f65a4786.jpg
Hangzhou, China - Feb. 19, 2026 - Nihaojewelry, a global online wholesale jewelry [https://www.nihaojewelry.com/] supplier, has announced that its Mexico warehouse will continue normal shipping operations and offer promotional discounts throughout the upcoming Chinese New Year holiday period (February 9-21), ensuring uninterrupted service for international customers during a time when global logistics often face disruptions.
Every year during the Chinese Lunar New Year, supply chains experience cyclical strains. According to…
More Releases for Severe
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage
The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS).
The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763
This latest report researches the industry structure, sales, revenue,…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…
